Apply to trial NCT07280585

A few quick questions so the study team can decide if you might be a fit.

RecruitingPhase 3Drug trial

STOP-PKD: SGLT2-inhibition to Improve Prognosis in Polycystic Kidney Disease

Autosomal dominant polycystic kidney disease is the most common genetic cause of kidney failure. The only approved treatment for ADPKD - tolvaptan - is limited in its use by massive therapy-associated polyuria. This trial tests if the SGLT2-inhibitor dapagliflozin slows down the loss of kidney function in ADPKD.

How this works

Answer a few questions
About 5 to 10 minutes. Skip-friendly where possible.
We connect you with the study team
When a site picks up your application, we introduce you to their team directly — with you on the thread.
The team reaches out to schedule screening
Usually within a few business days, via the contact you give.

EmailWe save your progress under this email and copy you when we connect you with the study team.

I agree that Hipa.ai may share my application — my name, contact details, and my answers, including health information — with the official study team for this trial so they can review my responses and contact me.

By continuing, you agree to our terms of service.

STOP-PKD: SGLT2-inhibition to Improve Prognosis in Polycystic Kidney Disease

How this works

Answer a few questions

We connect you with the study team

The team reaches out to schedule screening